Health economic model assumptions of pharmaceutical treatment paths compared with real-world evidence for patients with type 2 diabetes: A nationwide cohort study

2OBJECTIVEThe glucagon-like peptide-1 (GLP1) and sodium-glucose co-transporter-2 (SGLT2) classes are increasingly being used around the globe to treat type 2 diabetes and its comorbidities. Decision-analytical models (DAMs) are used to evaluate the cost-effectiveness of the different products within these classes, but their assumptions regarding the treatment pathways and time until insulin may not reflect real-world practice. This study compares the model assumptions found in a recent review with registry data. RESEARCH DESIGN AND METHODSReal-world practice was represented by a nationwide registry-based cohort of 62,238 people with type 2 diabetes included in an early (2012 to 2018), and a late period (2019 to 2021). Treatment pathway assumptions were compared using counts and proportions. Time until insulin initiation was compared among groups starting on the comparators dipeptidyl peptidase-4 inhibitor (DPP4), GLP1, or SGLT2. Incidence rates, hazard ratios, and absolute risks were utilized. The latter were derived from cumulative incidence functions calculated using the Aalen-Johansen estimator, accounting for competing risks. RESULTSThe treatment pathway assumptions of initiating insulin after a short time on the comparators did not correspond with our data. Neither did the assumptions surrounding time until insulin, as the time differed between comparator group, and inclusion period, with SGLT2 having the lowest risk. Further, time until insulin was observed to be much longer in real-world practice than in the model assumptions. CONCLUSIONSKey model assumptions used to inform decision-makers on the cost-effectiveness of expensive drug classes like GLP1 and SGLT2, are flawed and need to be updated.